SpringWorks Therapeutics Inc. has announced an update regarding its merger with Merck KGaA, Darmstadt, Germany. According to the company, the Merger Agreement, which was initially disclosed on April 27, 2025, has been approved by SpringWorks' board of directors. Under the agreement, EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, will merge with SpringWorks, resulting in SpringWorks becoming a wholly owned subsidiary of Merck KGaA. The merger is anticipated to be completed in the second half of 2025, pending satisfaction of customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-059579), on June 16, 2025, and is solely responsible for the information contained therein.
Comments